Characterization of a First-Pass Gradient-Echo Spin-Echo Method to Predict Brain Tumor Grade and Angiogenesis

References

1. ↵
   (1996) 1996 Annual Report. Central Brain Tumor Registry for the United States.
2. ↵
   Third National Cancer Survey. US National Cancer Institute;1989
3. ↵
   Leon SP, Folkerth RD, Black P. Microvessel density is a prognostic indicator for patients with astroglial brain tumors. Cancer 1996;77:362–372

   CrossRefPubMedWeb of Science
4. ↵
   Assimakopoulou M, Sotiropoulou-Bonikou G, Maraziotis T, Papadakis N, Varakis I. Microvessel density in brain tumors. Anticancer Res 1997;17:4747–4754

   PubMed
5. ↵
   Bello L, Carraba G, Giussani C, et al. Low-dose chemotherapy combined with antiangiogenic drug reduces human glioma growth in vivo. Cancer Res 2001;61:7501–7506

   Abstract/FREE Full Text
6. Bergers G, Javaherian K, Lo K, Folkman J, Hanahan D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 1999;284:808–812

   Abstract/FREE Full Text
7. ↵
   Bernsen HJ, Rijken PF, Peters JP, Bakker H, Kogel AJVD. Delayed vascular changes after angiogenic therapy with antivascular endothelial growth factor antibodies in human glioma xenografts in nude mice. Neurosurgery 1998;43:570–576

   CrossRefPubMedWeb of Science
8. ↵
   Bernsen HJ, Rijken PF, Peters JP, et al. Suramin treatment of human glioma xenografts; effects on tumor vasculature and oxygenation status. J Neuro-Oncol 1999;44:129–136

   CrossRefPubMed
9. ↵
   Rosen BR, Belliveau JW, Vevea JM, Brady TJ. Perfusion imaging with NMR contrast agents. Magn Reson Med 1990;14:249–265

   PubMedWeb of Science
10. ↵
    Maeda M, Itoh S, Kimura H, et al. Tumor vascularity in the brain: evaluation with dynamic susceptibility-contrast MR imaging. Radiology 1993;189:233–238

    PubMedWeb of Science
11. Aronen HJ, Cohen MS, Belliveau JW, Fordham JA, Rosen BR. Ultrafast imaging of brain tumors. Top Magn Reson Imaging 1993;5:14–24

    PubMed
12. ↵
    Aronen HJ, Gazit IE, Louis DN, et al. Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. Radiology 1994;191:41–51

    PubMedWeb of Science
13. Guckel F, brix G, Rempp K, Deimling M, Rother J, Georgi M. Assessment of cerebral blood volume with dynamic susceptibility contrast enhanced gradient-echo imaging. J Comput Assist Tomogr 1994;18:344–351

    PubMedWeb of Science
14. ↵
    Bruening R, Kwong KK, Vevea MJ, et al. Echo-planar MR determination of relative cerebral blood volume in human brain tumors: T1 versus T2 weighting. AJNR Am J Neuroradiol 1996;17:831–840

    Abstract
15. ↵
    Siegal T, Rubinstein R, Tzuk-Shina T, Gomori JM. Utility of relative cerebral blood volume mapping derived from perfusion magnetic resonance imaging in the routine follow up of brain tumors. J Neurosurg 1997;86:22–27

    PubMedWeb of Science
16. Boxerman JL, Rosen BR, Weisskoff RM. Signal-to-noise analysis of cerebral blood volume maps from dynamic NMR imaging studies. J Magn Reson Imaging 1997;7:528–537

    PubMed
17. Hacklander T, Reichenbach JR, Modder U. Comparison of cerebral blood volume measurements using the T1 and T2* methods in normal human brains and brain tumors. J Comput Assist Tomogr 1997;21:857–866

    CrossRefPubMed
18. Hou L, Yang Y, Mattay VS, Frank JA, Duyn JH. Optimization of fast acquisition methods for whole-brain relative cerebral blood volume (rCBV) mapping with susceptibility contrast agents. J Magn Reson Imaging 1999;9:233–239

    CrossRefPubMed
19. ↵
    Donahue KM, Krouwer HGJ, Rand SD, et al. Utility of simultaneously acquired gradient-echo and spin-echo cerebral blood volume and morphology maps in brain tumor patients. Magn Reson Med 2000;43:845–853

    CrossRefPubMedWeb of Science
20. Zhu XP, Li KL, Kamaly-Asl ID, et al. Quantification of endothelial permeability, leakage space, and blood volume in brain tumors using combined T1 and T2* contrast-enhanced dynamic MR imaging. J Magn Reson Imaging 2000;11:575–585

    CrossRefPubMedWeb of Science
21. ↵
    Aronen HJ, Pardo FS, Kennedy DN, et al. High microvascular blood volume is associated with high glucose uptake and tumor angiogenesis in human gliomas. Clin Cancer Res 2000;6:2189–2200

    Abstract/FREE Full Text
22. ↵
    Sugahara T, Jorogi Y, Tomiguchi S, et al. Posttherapeutic intraaxial brain tumor: the value of perfusion-sensitive contrast-enhanced MR imaging for differentiating tumor recurrence from nonneoplastic contrast-enhancing tissue. AJNR Am J Neuroradiol 2000;21:901–909

    Abstract/FREE Full Text
23. ↵
    Sugahara T, Korogi Y, Kochi M, Ushio Y, Takahashi M. Perfusion-sensitive MR imaging of gliomas: comparison between gradient-echo and spin-echo echo-planar imaging techniques. AJNR Am J Neuroradiol 2001;22:1306–1315

    Abstract/FREE Full Text
24. Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared to conventional imaging. AJNR Am J Neuroradiol 2003;24:1989–1998

    Abstract/FREE Full Text
25. Knopp EA, cha S, Johnson G, et al. Glial neoplasms: dynamic contrast-enhanced T2*-weighted MR imaging. Radiology 1999;211:791–798

    CrossRefPubMedWeb of Science
26. Lam WW, Chan KW, Wong WL, Poon WS, Metreweli C. Pre-operative grading of intracranial glioma. Acta Radiol 2001;42:548–554

    PubMed
27. Yang D, Korogi Y, Sugahara T, et al. Cerebral gliomas: prospective comparison of multivoxel 2D chemical-shift imaging proton MR spectroscopy, echoplanar perfusion and diffusion-weighted MRI. Neuroradiology 2002;44:656–666

    CrossRefPubMed
28. Kremer S, Grand S, Remy C, et al. Cerebral blood volume mapping by MR imaging in the initial evaluation of brain tumors. J Neuroradiol 2002;29:105–113

    PubMed
29. ↵
    Sugahara T, Korogi Y, Shigematsu Y, et al. Value of dynamic susceptibility contrast magnetic resonance imaging in the evaluation of intracranial tumors. Top Magn Reson Imaging 1999;10:114–124

    PubMed
30. ↵
    Cha S, Knopp EA, Johnson G, et al. Dynamic contrast-enhanced T2-weighted MRI imaging of recurrent malignant gliomas treated with thalidomide and carboplatin. AJNR Am J Neuroradiol 2000;21:881–890

    Abstract/FREE Full Text
31. ↵
    Fuss M, Wenz F, Essig M, et al. Tumor angiogenesis of low-grade astrocytomas measured by dynamic susceptibility contrast-enhanced MRI (DSC-MRI) is predictive of local tumor control after radiation therapy. Int J Radiat Oncol Biol Physics 2001;51:478–482

    CrossRefPubMed
32. ↵
    Fisel CR, Ackerman JL, Buxton RB, et al. MR contrast due to microscopically heterogeneous magnetic susceptibility: numerical simulations and applications to cerebral physiology. Magn Reson Med 1991;17:336–347

    PubMedWeb of Science
33. ↵
    Boxerman JL, Hamberg LM, Rosen BR, Weisskoff RM. MR contrast due to intravascular magnetic susceptibility perturbations. Magn Reson Med 1995;34:555–566

    CrossRefPubMedWeb of Science
34. ↵
    Majumdar S, Zoghbi S, Gore JC. The influence of pulse sequence on the relaxation effects of superparamagnetic iron oxide contrast agents. Magn Reson Med 1989;10:289–301

    PubMedWeb of Science
35. ↵
    Dennie J, Mandeville JB, Boxerman JL, Packard SD, Rosen BR, Weisskoff RM. NMR imaging of changes in vascular morphology due to tumor angiogenesis. Magn Reson Med 1998;40:793–799

    PubMedWeb of Science
36. ↵
    Tropres I, Grimault S, Vaeth A, et al. Vessel size imaging. Magn Reson Med 2001;45:397–408

    CrossRefPubMedWeb of Science
37. ↵
    Kleihues P, Burger PC, Scheithauer BW. Histological Typing of Tumours of the Central Nervous System. New York: Springer-Verlag,1993
38. ↵
    Weisskoff RM, Boxerman JL, Sorensen AG, Kulke SM, Campbell TA, Rosen BR. Simultaneous blood volume and permeability mapping using a single Gd-based contrast injection. Presented at: 2nd Annual Meeting of the Society of Magnetic Resonance in Medicine;1997; San Francisco, CA
39. ↵
    Webb A. Statistical Pattern Recognition. New York: Oxford University Press,1999
40. ↵
    Holash J, Maisonpierre PC, Compton D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999;284:1994–1998

    Abstract/FREE Full Text
41. ↵
    Plate KH, Mennei HD. Vascular morphology and angiogenesis in glial tumors. Exp Toxicol Pathol 1995;47:89–94

    CrossRefPubMedWeb of Science
42. ↵
    Kleihues P, Louis DN, Scheithauer BW, et al. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 2002;61:215–225

    PubMedWeb of Science
43. ↵
    Burger PC, Vogel FS, Green SB, Strike TA. Glioblastoma multiforme and anaplastic astrocytoma: pathologic criteria and prognostic implications. Cancer 1985;56:1106–1111

    CrossRefPubMedWeb of Science
44. ↵
    Vajkoczy P, Menger MD. Vascular microenvironment in gliomas. J Neuro-Oncol 2000;50:99–108

    CrossRefPubMed
45. ↵
    Guo P, Xu L, Pan S, et al. Vascular endothelial growth factor isoforms display distinct activities in promoting tumor angiogenesis at different anatomic sites. Cancer Res 2001;61:8569–8577

    Abstract/FREE Full Text
46. ↵
    Plate KH, Breier G, Weich HA, Mennel HD, Risau W. Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms. Int J Cancer 1994;59:520–529

    CrossRefPubMedWeb of Science
47. ↵
    Yuan F, Chen Y, Dellian M, Safabakhsh N, Ferrara N, Jain RK. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an antivascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci 1996;93:14765–14770

    Abstract/FREE Full Text
48. Allegrini PR, Muller-Driver R, Wittig C, Konerding M, Drevs J, Wood J. Effect of PTK787, a specific VEGF receptor tyrosine kinase inhibitor, on anatomy, density and permeability of tumor vessels in murine renal cell carcinoma (RENCA). Presented at: 10th Annual Meeting of the International Society of Magnetic Resonance in Medicine;2002; Honolulu, HI
49. Teicher BA, Dupuis N, Kusomoto T, et al. Antiangiogenic agents can increase tumor oxygenation and responses to radiation therapy. Radiat Oncol Invest 1995;2:269–276
50. ↵
    Kakeji Y, Teicher BA. Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents. Invest New Drugs 1997;15:39–48

    CrossRefPubMedWeb of Science
51. ↵
    Novak K. Angiogenesis inhibitors revised and revived at AACR. Nat Med 2002;8:427

    PubMed
52. ↵
    Kiselev VG. On the theoretical basis of perfusion measurements by dynamic susceptibility contrast MRI. Magn Reson Med 2001;46:1113–1122

    CrossRefPubMedWeb of Science
53. Pathak AP, Schmainda KM, Ward BD, Linderman JR, Rebro KJ, Greene AS. MR-derived cerebral blood volume maps: issues regarding histological validation and assessment of tumor angiogenesis. Magn Reson Med 2001;46:735–747

    CrossRefPubMedWeb of Science
54. Calamante F, Gadian DG, Connelly A. Delay and dispersion effects in dynamic susceptibility contrast MRI: simulations using singular value decomposition. Mag Reson Med 2000;44:466–473

    CrossRefPubMed
55. Pathak AP, Ward BD, Rebro KJ, Schmainda KM. The effect of brain tumor angiogenesis on the in vivo relationship between contrast agent (MION) and the gradient-echo relaxation rate change (DR2*). Presented at: 10th Annual Meeting of the International Society of Magnetic Resonance in Medicine;2002; Honolulu, HI
56. Perkio J, Aronen HJ, Kangasmaki A, et al. Evaluation of four postprocessing methods for determination of cerebral blood volume and mean transit time by dynamic susceptibility contrast imaging. Magn Reson Med 2002;47:973–981

    CrossRefPubMedWeb of Science
57. ↵
    Cha S, Knopp EA, Johnson G, Wetzel SG, Litt AW, Zagzag D. Intracranial mass lesions: dynamic contrast-enhanced susceptibility-weighted echo-planar perfusion MR imaging. Radiology 2002;223:11–29

    CrossRefPubMedWeb of Science
58. ↵
    Pathak AP, Rand SD, Schmainda KM. The effect of brain tumor angiogenesis on the in vivo relationship between the gradient-echo relaxation rate change (ΔDR2*) and contrast agent (MION) dose. J Magn Reson Imaging 2003;18:397–403

    CrossRefPubMedWeb of Science
59. ↵
    Schmainda KM, Rand SD, Joseph AM, et al. Dynamic gradient-echo and spin-echo measurements of tumor blood volume and vascular morphology predict grade in patients with brain tumors. Presented at: International Society of Magnetic Resonance in Medicine–Workshop on In Vivo Functional and Molecular Assessment of Cancer. Santa Cruz, CA;2002
60. ↵
    Schmainda KM, Rand SD, Joseph AM, et al. A combined gradient-echo / spin-echo DSC method: a surrogate marker for brain tumor histologic grade and angiogenesis in patients. Presented at: 11th Annual Meeting of International Society of Magnetic Resonance in Medicine.2003; Toronto, Ontario, Canada
61. ↵
    Enochs WS, Harsh G, Hochberg F, Weissleder R. Improved delineation of human brain tumors on MR images using a long-circulating, superparamagnetic iron oxide contrast agent. J Magn Reson Imaging 1999;9:228–232

    CrossRefPubMedWeb of Science